abstract: BACKGROUND: Hemeproteins such as free myoglobin can undergo autoxidation and catalyse lipid peroxidation, increasing oxidative stress. @entity908 phosphokinase (CPK) elevation is a marker for free myoglobin after myocyte damage. Since oxidative injury is a key mechanism of @entity66 , we hypothesised that serum CPK levels correlate with mortality and need for inotropic medication and duration of inotropic support, i.e. shock, among critically injured @entity1 . METHODS: We conducted a retrospective review of 17,847 @entity1 admitted to a single @entity130 Intensive Care Unit over 9 years. 2583 patients with serum CPK levels were included in the analysis. @entity1 data were collected continuously into an electronic ICU repository. Univariate analysis was accomplished using Spearman correlation and the Mann-Whitney U test. Propensity score adjustment models accounting for potential confounders were used to assess the independent effect of CPK level on mortality, need for inotropic support, and duration of inotropic support. RESULTS: Median CPK was significantly higher in @entity1 who died (916 [IQR 332, 2472] vs. 711 [253, 1971], p=0.004) and in those who required inotropic medications (950 [353, 2525] vs. 469 [188, 1220], p<0.001). After adjusting for propensity score and potential confounders the odds of mortality increased by 1.10 (95% CI 1.02-1.19, p=0.020) and the odds of inotropic medication use increased by 1.30 (95% CI 1.22-1.38, p<0.001) per natural log unit increase in CPK. There was a significant association between CPK level and duration of inotropic support (Spearman's rho .237, p<0.001) that remained significant in a propensity score-adjusted model. CONCLUSION: In critically injured patients, elevated serum CPK level is independently associated with mortality, need for inotropic medication, and duration of inotropic support. This study is the first to evaluate the relationship of CPK level and mortality in addition to surrogate measures of shock in a population of critically injured @entity1 . If these associations are verified prospectively, there may be a role for treatment with @entity68480 reductants, such as @entity1443 , to mitigate the effects of @entity881 .

title: Elevated serum XXXX phosphokinase is associated with mortality and inotropic requirement in critically injured adults.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patient']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['injury-related organ dysfunction']

entities_list: @entity908 :: ('MESH:D003401', 'Chemical') :: ['Creatine']

entities_list: @entity881 :: ('MESH:D009102', 'Disease') :: ['shock and end-organ dysfunction']

entities_list: @entity1443 :: ('MESH:D000082', 'Chemical') :: ['paracetamol']

entities_list: @entity68480 :: ('CHEBI:35137', 'Chemical') :: ['hemeprotein']

answer: @entity908 :: (MESH:D003401,Chemical) :: ['creatine']


abstract: UNASSIGNED: OBJECT Case selection for the surgical treatment of @entity2758 ( @entity2758 ) of the eloquent motor area remains challenging. The aim of this study was to determine the risk factors for worsened @entity121 after surgery in @entity1 with this disorder. METHODS At their hospital the authors retrospectively studied 48 consecutive @entity1 with @entity2758 involving motor cortex and/or the descending pathway. All @entity1 had undergone preoperative functional MRI (fMRI) and diffusion tensor imaging (DTI), followed by resection. Both functional and angioarchitectural factors were analyzed with respect to the change in @entity121 . Functional factors included @entity75 ( @entity75 ) on DTI and lesion-to-activation area distance (LAD) and cortical reorganization on fMRI. Based on preoperative @entity121 , the changes in @entity121 at 1 week and 6 months after surgery were defined as short-term and long-term surgical outcomes, respectively. Statistical analysis was performed using the statistical package SPSS (version 20.0.0, IBM Corp.). RESULTS Twenty-one @entity1 (43.8%) had worsened @entity121 1 week after surgery. However, only 10 @entity1 (20.8%) suffered from @entity121 worsening 6 months after surgery. The @entity75 was significantly correlated with short-term (p < 0.001) and long-term (p < 0.001) surgical outcomes. For long-term outcomes, @entity1 in the 5 mm >=  @entity75 > 0 mm (p = 0.009) and @entity75 > 5 mm (p < 0.001) categories were significantly associated with a lower risk of permanent motor worsening in comparison with @entity1 in the @entity75 = 0 mm group. No significant difference was found between @entity1 in the 5 mm >=  @entity75 > 0 mm group and @entity75 > 5 mm group (p = 0.116). Nidus size was the other significant predictor of short-term (p = 0.021) and long-term (p = 0.016) outcomes. For long-term outcomes, the area under the ROC curve (AUC) was 0.728, and the cutoff point was 3.6 cm. Spetzler-Martin grade was not associated with short-term surgical outcomes (0.143), although it was correlated with long-term outcomes (0.038). CONCLUSIONS An @entity7026 with a nidus in contact with tracked eloquent fibers ( @entity75 = 0) and having a large size is more likely to be associated with worsened @entity121 after surgery in @entity1 with eloquent motor area @entity2758 . Surgical treatment in these @entity1 should be carefully considered. In @entity1 with an @entity75 > 5 mm, radical resection may be considered to eliminate the risk of @entity548 .

title: Risk factors for worsened @entity121 after the surgical treatment of XXXX of the eloquent motor area.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2758 :: ('MESH:D001165', 'Disease') :: ['arteriovenous malformations', 'AVMs']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['LCD', 'lesion-to-corticospinal tract distance']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['muscle strength']

answer: @entity2758 :: (MESH:D001165,Disease) :: ['arteriovenous malformations']


abstract: @entity788 frequently recurs in @entity1 even after resection with curative intent. The majority of these are early recurrences and are associated with @entity3 , thus not amenable to repeat resection. Here we report a @entity1 who underwent completion pancreatectomy for a metachronous @entity788 . This @entity1 initially presented with painless @entity1087 and computed tomography (CT) revealed a mass in the head of the pancreas. Brushings obtained at endoscopic retrograde cholangiopancreatography (ERCP) were positive for @entity420 . This @entity1 then underwent a Whipple procedure and final pathology demonstrated @entity788 . Adjuvant therapy included @entity136 and @entity3866 . This @entity1 was followed with physical examinations and serial laboratory and imaging studies. There was no evidence of disease for four years at which time and sharp elevation in CA-19-9 was found. Subsequent imaging revealed a mass in the remnant pancreas. Curative intent completion pancreatectomy was then performed which confirmed the presence of @entity788 . This was followed by adjuvant @entity136 based chemotherapy and chemoradiation. One year later the @entity1 is alive with no evidence of disease. Thus, in highly selected @entity1 with recurrent or metachronous @entity788 , repeat pancreatectomy can be considered, but the course of treatment should be considered in a multidisciplinary setting.

title: Resection of metachronous XXXX 4  years after pancreaticoduodenectomy for stage III @entity788 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['Pancreatic adenocarcinoma', 'pancreatic cancer', 'stage III pancreatic ductal adenocarcinoma', 'pancreatic adenocarcinoma']

entities_list: @entity136 :: ('MESH:C056507', 'Chemical') :: ['Gemcitabine', 'gemcitabine']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']

entities_list: @entity3866 :: ('MESH:C400278', 'Chemical') :: ['erlotinib']

answer: @entity788 :: (MESH:D010190,Disease) :: ['pancreatic cancer']


abstract: PURPOSE: To determine if there is a difference in intervention patency for @entity1211 ( @entity1211 ) and occlusion between @entity1 with autogenous hemodialysis @entity292 and those with grafts. MATERIAL AND METHODS: A retrospective study was performed from March 1998 to September 2005 identifying all @entity1 with autogenous @entity292 and synthetic grafts who underwent percutaneous angioplasty and/or stent placement for @entity1211 . This study cohort consisted of 38 @entity1 (22 with @entity292 and 16 with grafts). Age, sex, type of access, location and side of the access, location and side of the @entity1211 , presence of @entity6 , previous hemodialysis catheter placement, date and type of interventions, and outcomes were recorded. The patency of each intervention was estimated by using the Kaplan-Meier survival curves. Univariate and multivariate analysis of the variables were performed. RESULTS: Eighty-nine interventions were performed; 83 were angioplasties and six were stent placements. Previous catheter placement on the side of the @entity1211 occurred in 29 of the 38 @entity1 (76%). Technical and clinical success of the interventions were 93.3% and 94.4% respectively. The intervention or primary patency rates +/- standard errors at 3, 6, and 9 months in the fistula group were 88.5% +/- 4.8, 59.4% +/- 7.6, and 46% +/- 7.9, respectively. In the graft group, the rates were 78.1% +/- 7.3, 40.7% +/- 9, and 16% +/- 7.3, respectively. With multivariate analysis, intervention patency remained significantly longer for @entity292 (P .014) and in @entity1 who did not have a previous catheter (P .001). CONCLUSION: Longer intervention-free survival for @entity1211 was observed in @entity1 with autogenous @entity292 compared with grafts and in @entity1 who did not previously undergo hemodialysis catheter insertion.

title: Patency of endovascular treatment for XXXX : is there a difference between dialysis @entity292 and grafts?

entities_list: @entity1211 :: ('MESH:D054556', 'Disease') :: ['central venous stenosis', 'CVS']

entities_list: @entity292 :: ('MESH:D005402', 'Disease') :: ['fistulas']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

answer: @entity1211 :: (MESH:D054556,Disease) :: ['central venous stenosis']


abstract: UNASSIGNED: @entity5 is associated with @entity281 by certain types of @entity1082 ). The gene variants differ in immune responses and oncogenic potential. The @entity32454 proteins encoded by high-risk HPV play a key role in cellular transformation. HPV-33 and HPV-58 types are highly prevalent among Chinese @entity1 . To study the gene intratypic variations, polymorphisms and positive selections of HPV-33 and HPV-58 E6/E7 in southwest China, HPV-33 (E6, E7: n = 216) and HPV-58 (E6, E7: n = 405) @entity32454 genes were sequenced and compared to others submitted to GenBank. Phylogenetic trees were constructed by Maximum-likelihood and the Kimura 2-parameters methods by MEGA 6 (Molecular Evolutionary Genetics Analysis version 6.0). The diversity of secondary structure was analyzed by PSIPred software. The selection pressures acting on the E6/E7 genes were estimated by PAML 4.8 (Phylogenetic Analyses by Maximun Likelihood version4.8) software. The positive sites of HPV-33 and HPV-58 E6/E7 were contrasted by ClustalX 2.1. Among 216 HPV-33 E6 sequences, 8 single @entity4334 mutations were observed with 6/8 non-synonymous and 2/8 synonymous mutations. The 216 HPV-33 E7 sequences showed 3 single @entity4334 mutations that were non-synonymous. The 405 HPV-58 E6 sequences revealed 8 single @entity4334 mutations with 4/8 non-synonymous and 4/8 synonymous mutations. Among 405 HPV-58 E7 sequences, 13 single @entity4334 mutations were observed with 10/13 non-synonymous mutations and 3/13 synonymous mutations. The selective pressure analysis showed that all HPV-33 and 4/6 HPV-58 E6/E7 major non-synonymous mutations were sites of positive selection. All variations were observed in sites belonging to major histocompatibility complex and/or B-cell predicted epitopes. @entity69288 and R145 (I/N) were observed in both HPV-33 and HPV-58 E6.

title: @entity32454 Gene Polymorphisms in XXXX Types-58 and 33 Identified in Southwest China.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer of the cervix']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity1082 :: ('10566', 'Species') :: ['human papillomavirus (HPV']

entities_list: @entity69288 :: ('p|SUB|K|93|N', 'ProteinMutation') :: ['K93N']

answer: @entity1082 :: (10566,Species) :: ['Human Papillomavirus']


abstract: UNASSIGNED: This study was designed to investigate the prognostic impact of elevated platelet to lymphocyte ratio (PLR) on survival for @entity420 ( @entity420 ) treated with neoadjuvant chemotherapy in a curative intent. From 2004 to 2014, 153 consecutive @entity1 with @entity420 were included. PLR was measured at first diagnosis. Receiver Operating Characteristic curve analysis was performed to determinate PLR threshold. Cox multivariate model was used to assess correlation between PLR and survival. Cut-off value for PLR was 192, which identified 2 groups of @entity1 : low (n  =  122) and high PLR value (n  =  31). Both groups were comparable by @entity1 (age, sex, ASA score) and @entity5 characteristics (differentiation, @entity2802 stage, location). Five year @entity1349 ( @entity1349 ) was 65%. @entity1349 and DFS were reduced in the high PLR group: p  =  0.019 and p  =  0.016, respectively. PLR was associated with increased recurrence (54.8% vs. 35.2%, p  =  0.046) and @entity5 (41.9% vs. 23.8%, p  =  0.043) rates. On multivariate analysis, elevated PLR was associated with decreased DFS (HR  =  2.85, 95%CI  =  1.54-5.26, p  =  0.001) and @entity1349 (HR  =  2.47, 95%CI  =  1.21-5.01, p  =  0.012). This study demonstrates that elevated PLR is associated with poor @entity1349 and DFS for @entity420 treated with a curative intent and has the potential to be a useful prognostic biomarker for treatment planning.

title: Prognostic impact of preoperative platelets to lymphocytes ratio (PLR) on survival for oesophageal and junctional carcinoma treated with neoadjuvant chemotherapy: A retrospective monocentric study on 153 XXXX .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer-related death', 'tumour']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['oesophageal and junctional adenocarcinoma', 'OJA']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVES: To estimate the prevalence of @entity66 in aged care facilities, and the relationship between cognitive or @entity717 and significant disease. SETTING: 2 large aged care facilities in Auckland, New Zealand, each providing low and high level care. @entity1 : All 161 residents of the facilities were invited to participate. The only exclusion criterion was inability to obtain consent from the individual or designated guardian. 88 @entity1 were recruited-66 females (75%), 22 males (25%) with average age 87.1   years (SD 5.5   years). PRIMARY AND SECONDARY OUTCOME MEASURES: Primary-presence of significant @entity272 (defined as that which in the opinion of the investigators needed treatment or was identified as a @entity1 concern) diagnosed clinically on full dermatological examination by a dermatologist or dermatology trainee. Secondary-functional and cognitive status (Rehabilitation Complexity Scale and Abbreviated Mental Test Score). RESULTS: 81.8% were found to have at least one significant condition. The most common disorders were @entity6313 42 (47.7%), @entity1491 13 (14.8%), @entity484 11 (12.5%) and @entity957 in situ 9 (10.2%). Other findings were @entity957 7 (8%), bullous pemphigoid 2 (2.3%), @entity320 2 (2.3%), @entity3854 (2.3%) and @entity0 (1.1%). @entity32 was more common in those with @entity717 compared with those with serious @entity717 (OR 3.69; 95% CI 1.1 to 12.6, p=0.04). No significant association was found between @entity272 and @entity73 . CONCLUSIONS: A high rate of @entity66 was found. Findings ranged from frequent but not life-threatening conditions (eg, @entity6313 ), to those associated with a significant morbidity (eg, @entity484 , @entity3854 and bullous pemphigoid), to potentially life-threatening (eg, @entity957 , @entity320 and @entity0 ). Those with less significant @entity73 were found to be at greater risk of inflammatory dermatoses.

title: XXXX in the older age group: a cross-sectional study in aged care facilities.

entities_list: @entity1 :: ('9606', 'Species') :: ['patient', 'PARTICIPANTS', 'participants']

entities_list: @entity3854 :: ('MESH:D018459', 'Disease') :: ['lichen sclerosus 2', 'lichen sclerosus']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['Inflammatory disease']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['dermatological disease']

entities_list: @entity484 :: ('MESH:D004485', 'Disease') :: ['asteototic eczema', 'eczema']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'carcinoma of the breast 1']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive impairment', 'physical impairment']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['invasive squamous cell carcinoma', 'squamous cell carcinoma']

entities_list: @entity6313 :: ('MESH:D014009', 'Disease') :: ['onychomycosis']

entities_list: @entity272 :: ('MESH:D012871', 'Disease') :: ['skin disease']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['physical disability', 'little physical disability']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma']

entities_list: @entity1491 :: ('MESH:D002280', 'Disease') :: ['basal cell carcinoma']

answer: @entity66 :: (MESH:D004194,Disease) :: ['Dermatological disease']


abstract: OBJECTIVE: We aimed to assess whether the dosing regimen of @entity1307 shows a relationship to mortality in critically ill @entity1 with @entity131 ( @entity131 ). BACKGROUND: @entity1307 may decrease mortality in @entity1 with @entity131 ; however, the optimal dosing regimen remains uncertain. METHODS: We conducted a post-hoc analysis of a multicenter, randomized trial of weekly @entity1307 versus placebo in @entity1 with moderate and severe @entity131 admitted to intensive care. We assessed whether the cumulative dosage of @entity1307 was differentially associated with all-cause @entity1 mortality evaluated at 6 months after injury. RESULTS: There was a nonlinear relationship between dose and mortality (P = 0.008) that remained after adjustment for site and severity of illness (P = 0.01). Six-month mortality was lower in randomized @entity1 who received 1 [adjusted hazard ratio (HR) 0.58, 95% confidence interval (CI) 0.33-1.01; P = 0.06] or 2 doses of @entity1307 (HR 0.31, 95% CI 0.12-0.80; P = 0.02) compared with those who received no doses. No benefit was seen with 3 doses (HR 1.55, 95% CI 0.66-3.62; P = 0.33). There was no differential effect of dose on functional neurological outcomes. Results across subgroups and secondary intention to treat analyses were consistent with primary findings. CONCLUSIONS: This post-hoc, hypothesis-generating analysis found potential reductions in mortality following 1 or 2 weekly doses of 40,000 IU of @entity1307 in intensive care unit @entity1 with moderate or severe @entity131 , but not with 3 doses. These findings will inform the design of future trials of @entity1307 in critically ill @entity1 with @entity131 and @entity130 .

title: @entity1307 to Reduce Mortality in XXXX : A Post-hoc Dose-effect Analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity131 :: ('MESH:D001930', 'Disease') :: ['TBI', 'traumatic brain injury']

entities_list: @entity1307 :: ('2056', 'Gene') :: ['erythropoietin', 'Erythropoietin']

answer: @entity131 :: (MESH:D001930,Disease) :: ['Traumatic Brain Injury']


abstract: UNASSIGNED: @entity1 suffering from @entity308 often experience @entity2414 even after the remission of mood symptoms, and many antidepressant drugs do not affect, or impair, memory in animals and @entity1 . However, some antidepressant drugs, after a single dose, enhance cognition in @entity1 (Harmer et al., 2009). To compare different classes of antidepressant drugs for their potential as memory enhancers, we used a version of the novel object recognition task in which @entity35 spontaneously forget objects 24 hr after their presentation. Antidepressant drugs were injected systemically 30 min before or directly after the training phase (Session 1 [S1]). Post-S1 injections were used to test for specific memory-consolidation effects. The @entity1063 reuptake inhibitors @entity18891 and @entity4678 , as well as the @entity750 @entity1063 reuptake inhibitor @entity4480 , injected prior to S1 significantly enhanced recognition memory. In contrast, the @entity750 reuptake inhibitors @entity837 and @entity903 and the cyclic antidepressant drugs @entity5829 and @entity5079 did not enhance recognition memory. Post-S1 injection of either @entity18891 or @entity837 significantly enhanced recognition memory, indicating an effect on memory consolidation. The fact that @entity837 had an effect only when injected after S1 suggests that it may counteract its own consolidation-enhancing effect by interfering with memory acquisition. However, pretreatment with @entity837 did not attenuate @entity18891 's memory-enhancing effect. The D1/5-receptor antagonist @entity10095 blunted @entity18891 's memory-enhancing effect, indicating a role of dopaminergic transmission in @entity18891 -induced recognition memory enhancement. Our results suggest that antidepressant drugs specifically inhibiting @entity1063 reuptake enhance cognition and may be beneficial in the treatment of @entity308 . (PsycINFO Database Record

title: Antidepressant Drugs Specifically Inhibiting XXXX Reuptake Enhance Recognition Memory in @entity35 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'humans']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['cognitive symptoms of depression', 'major depression']

entities_list: @entity5079 :: ('MESH:D008803', 'Chemical') :: ['mianserin']

entities_list: @entity5829 :: ('MESH:D003891', 'Chemical') :: ['desipramine']

entities_list: @entity903 :: ('MESH:D017374', 'Chemical') :: ['paroxetine']

entities_list: @entity18891 :: ('MESH:C074679', 'Chemical') :: ['reboxetine']

entities_list: @entity837 :: ('MESH:D015283', 'Chemical') :: ['citalopram']

entities_list: @entity4678 :: ('MESH:C041930', 'Chemical') :: ['atomoxetine']

entities_list: @entity4480 :: ('MESH:C058218', 'Chemical') :: ['duloxetine']

entities_list: @entity750 :: ('MESH:D012701', 'Chemical') :: ['serotonin']

entities_list: @entity2414 :: ('MESH:D008569', 'Disease') :: ['memory deficits']

entities_list: @entity1063 :: ('MESH:D009638', 'Chemical') :: ['noradrenaline']

answer: @entity1063 :: (MESH:D009638,Chemical) :: ['Noradrenaline']


abstract: PURPOSE: To demonstrate the protective effect of @entity15212 ( @entity15212 ) signaling on the cardiovascular system, we conducted this study to show that the @entity17121 analog (lixisenatide) could inhibit @entity1028 ( @entity1028 ) development in @entity35 . METHODS: Lixisenatide was injected subcutaneously 7  days after @entity439 preparation. We evaluated reactive @entity26 species (ROS) expression by @entity16203 staining and @entity20821 ( @entity20821 ; the oxidation product of DNA) by immunohistochemical staining. We also analyzed the effect of @entity15212 signaling on the inflammatory response. Histopathological examination was done on day 28, and the @entity1028 dilatation ratio was calculated. RESULTS: On day 14, ROS expression and @entity20821 -positive cells in the @entity439 walls were seen to have been significantly decreased by lixisenatide treatment. Western blot analysis showed decreased @entity2509 expression. There was significantly reduced @entity5 necrosis factor-a mRNA expression in the @entity439 walls and @entity22519 -positive cell infiltration in the @entity439 walls. On day 28, it was evident that the lixisenatide had dramatically reduced @entity439 development in the @entity35 . CONCLUSION: @entity15212 elevation inhibits @entity1028 development in @entity35 through its anti-oxidant and anti-inflammatory effects. Thus, @entity15212 could be a potent pharmacological target for @entity1028 treatment.

title: XXXX prevented @entity1028 development in @entity35 .

entities_list: @entity20821 :: ('MESH:C067134', 'Chemical') :: ['8-hydroxydeoxyguanosine', '8-OHdG']

entities_list: @entity16203 :: ('MESH:C067883', 'Chemical') :: ['dihydroethidium']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysm']

entities_list: @entity1028 :: ('MESH:D017544', 'Disease') :: ['abdominal aortic aneurysm', 'AAA']

answer: @entity15212 :: (24952(Tax:10116),Gene) :: ['Glucagon-like peptide-1']


abstract: AIM: To evaluate the role of ultrasonography for differentiating @entity3799 due to @entity378 , @entity3 and @entity706 . METHODS: Ultrasonography of the neck nodes was carried out prior to FNAC in 192 @entity1 using a 10 mHz linear transducer. The sonographic findings were then correlated with the definitive tissue diagnosis obtained by FNAC or lymph node biopsy. RESULTS: The most significant distinguishing feature was strong internal echoes seen in 84% of tubercular lymph nodes. This finding was found in only 11% of metastatic nodes and absent in @entity1669 . The other findings such as L/S ratio, irregular margins, hypoechoic center, fusion tendency, peripheral halo and absent hilus were helpful in differentiating reactive from diseased nodes but showed considerable overlap in the 3 groups of tubercular, metastatic and @entity706 lymph nodes. CONCLUSION: Ultrasonography is noninvasive and can give useful clues in the diagnosis of @entity3799 . It should be interpreted in conjunction with FNAC result. Ideally ultra-sonographic guided FNAC should be obtained from the sonographically most representative node. In FNAC indeterminate cases, sonographic features may obviate the need for an invasive lymph node biopsy.

title: Usefulness of ultrasonography for the evaluation of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma']

entities_list: @entity1669 :: ('MESH:D013967', 'Disease') :: ['lymphomatous nodes']

entities_list: @entity3799 :: ('MESH:D002575', 'Disease') :: ['cervical lymphadenopathy']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity378 :: ('MESH:D014376', 'Disease') :: ['tuberculosis']

answer: @entity3799 :: (MESH:D002575,Disease) :: ['cervical lymphadenopathy']


abstract: BACKGROUND: @entity35343 phosphorylase (PyNPase) is identical to the protein, @entity1015 ( @entity1015 ), which has angiogenic activity. The physiological roles of PyNPase activity in the uterus and ovary are not known. In this study, we measured PyNPase activity in normal tissues of the uterus, ovary, and lymph nodes, and in benign and malignant lesions of these organs, and we considered the clinical implications of PyNPase activity in the uterus and ovary. METHODS: Tissue samples were obtained from 163 @entity1 (whose diseases are listed below) during surgery. PyNPase activity was measured spectrophotometrically, by monitoring the formation of @entity12244 . RESULTS: Mean PyNPase activity in tissues from the lesions of @entity1 with @entity5 (n = 20), uterine @entity1204 (n = 26), @entity2909 (n = 23), @entity43 (n = 46), @entity43 (n = 21), and @entity43 (n = 27) was significantly greater than that in the corresponding normal tissues. The PyNPase activity in the normal endometrium was significantly higher in the secretory phase than in the proliferative phase. The activity in normal or metastatic lymph nodes was significantly greater than that in normal tissues of the uterus and ovary. Mean PyNPase activity in cancerous cervical tissues was significantly greater than that in cancerous endometrial tissues or cancerous ovarian tissues. There were no significant differences in PyNPase activity in @entity5 , @entity43 tissues according to @entity5 stage. The enzyme activity appeared to be greater in histopathological G3 grade @entity1204 than in G1 and G2 @entity1204 . The enzyme activity in mucinous @entity420 was significantly lower than that in serous, endometrioid, and @entity16488 . All @entity1 with cervical @entity957 with PyNPase activity greater than 500 nmol/min per mg protein exhibited lymph node @entity3 . CONCLUSION: Increased PyNPase activity consistently reflected @entity5 , and varying levels of activity were seen in different histologic cell types. This enzyme activity may be involved in cervical @entity957 , in normal and metastatic lymph nodes, and in the normal, secretory phase in the endometrium.

title: XXXX phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.

entities_list: @entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial cancer']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian endometriosis', 'ovarian cancer', 'endometrial cancer, and ovarian cancer', 'benign epithelial ovarian tumor']

entities_list: @entity12244 :: ('MESH:C001943', 'Chemical') :: ['5-fluorouridine']

entities_list: @entity16488 :: ('MESH:D018262', 'Disease') :: ['clear cell adenocarcinomas']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cervical cancer', 'neoplastic growth']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinomas']

entities_list: @entity1015 :: ('1890', 'Gene') :: ['PD-ECGF', 'platelet-derived endothelial cell growth factor']

entities_list: @entity35343 :: ('CHEBI:26440', 'Chemical') :: ['Pyrimidine nucleoside']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma of the ovary']

entities_list: @entity2909 :: ('MESH:D007889', 'Disease') :: ['leiomyoma']

answer: @entity35343 :: (CHEBI:26440,Chemical) :: ['Pyrimidine nucleoside']


abstract: OBJECTIVES: Microbial @entity7944 ( @entity7944 ), such as @entity4334 -binding oligomerization domains (NODs), are essential for @entity1 innate immune response. This study was designed to determine the effect of @entity18506 and @entity6820 agonist on innate immune responses and antitumor activity in @entity957 ( @entity957 ) cells. MATERIALS AND METHODS: NODs expression was examined by RT-PCR, and @entity687 production by NODs agonist was examined by ELISA. Western blot analysis was performed to determine the MAPK activation in response to their agonist. Cell proliferation was determined by @entity98 assay. Flow cytometry and Western blot analysis were performed to determine the @entity7192 -induced cell death. RESULTS: The levels of NODs were apparently expressed in @entity957 cells. NODs agonist, Tri-DAP and @entity7192 , led to the production of @entity687 and MAPK activation. @entity6820 agonist, @entity7192 , inhibited the proliferation of YD-10B cells in a dose-dependent manner. Also, the ratio of @entity4404 -positive cells and cleaved @entity9190 was increased by @entity7192 treatment in YD-10B cells, suggesting that @entity7192 -induced cell death in YD-10B cells may be owing to apoptosis. CONCLUSIONS: Our results indicate that NODs are functionally expressed in @entity957 cells and can trigger innate immune responses. In addition, @entity6820 agonist inhibited cell proliferation and induced apoptosis. These findings provide the potential value of @entity7192 as novel candidates for antitumor agents of @entity957 .

title: @entity6820 ( XXXX ) activation induces apoptosis of @entity1 @entity957 cells.

entities_list: @entity1 :: ('9606', 'Species') :: ['mammalian']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['OSCC', 'oral squamous cell carcinoma']

entities_list: @entity7944 :: ('MESH:C536309', 'Disease') :: ['PRRs', 'Pattern-recognition receptors']

answer: @entity6820 :: (64127,Gene) :: ['NOD2']


abstract: BACKGROUND: @entity1545 ( @entity1545 ) has become one of the most common causes of @entity16 in developed countries. @entity73 result in a loss of independence and @entity1 ' quality of life. Cognitive rehabilitation aims to promote @entity1 ' skills to achieve their highest degree of personal autonomy. New technologies such as virtual reality or interactive video allow developing rehabilitation therapies based on reproducible Activities of Daily Living (ADLs), increasing the ecological validity of the therapy. However, the lack of frameworks to formalize and represent the definition of this kind of therapies can be a barrier for widespread use of interactive virtual environments in clinical routine. OBJECTIVES: To provide neuropsychologists with a methodology and an instrument to design and evaluate cognitive rehabilitation therapeutic interventions strategies based on ADLs performed in interactive virtual environments. METHODS: The proposed methodology is used to model therapeutic interventions during virtual ADLs considering @entity73 , expected abnormal interactions and therapeutic hypotheses. It allows identifying abnormal behavioural patterns and designing interventions strategies in order to achieve errorless-based rehabilitation. RESULTS: An ADL case study ('buying bread') is defined according to the guidelines established by the ADL intervention model. This case study is developed, as a proof of principle, using interactive video technology and is used to assess the feasibility of the proposed methodology in the definition of therapeutic intervention procedures. CONCLUSIONS: The proposed methodology provides neuropsychologists with an instrument to design and evaluate ADL-based therapeutic intervention strategies, attending to solve actual limitation of virtual scenarios, to be use for ecological rehabilitation of @entity73 in daily clinical practice. The developed case study proves the potential of the methodology to design therapeutic interventions strategies; however our current work is devoted to designing more experiments in order to present more evidence about its values.

title: Modelling Ecological Cognitive Rehabilitation Therapies for Building Virtual Environments in XXXX .

entities_list: @entity1545 :: ('MESH:D020214', 'Disease') :: ['Brain Injury', 'BI']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive deficit', 'Cognitive disorders']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological disability']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

answer: @entity1545 :: (MESH:D020214,Disease) :: ['Brain Injury']


abstract: UNASSIGNED: Anti- @entity5 drugs are discussed as high risk substances in regard to @entity1 health and considered as problematic for the environment. They are of potential environmental relevance due to their poor biodegradability and toxicological properties. @entity1499 ( @entity6822 ) is an antimetabolite that was introduced in the pharmaceutical market in the 40's and still today is one of the most consumed cytotoxic compounds around the world. In the present study @entity6822 was only partially biodegraded in the closed bottle test (CBT). Therefore, it was submitted to three different advanced oxidation processes (AOPs): UV/ @entity5568 , UV/ @entity8798 / @entity5568 and UV/ @entity3759 . The irradiation was carried out with a @entity5332 medium-pressure lamp during 256min whereas the analytical monitoring was done through LC-UV-MS/MS and DOC analysis. @entity6822 was easily removed in all the irradiation experiments, while the highest mineralization values and rates were achieved by the UV/ @entity8798 / @entity5568 treatment. The lowest resulted from the UV/ @entity5568 reactions. The UV/ @entity5568 treatment resulted in little biodegradable transformation products (TPs). However, the same treatment resulted in a reduction of the @entity137 of @entity6822 by forming less toxic TPs. Analysis by LC-UV-MS/MS revealed the existence of nine TPs formed during the photo-catalytic treatments. The pH of the solutions decreased from 6.4 (t 0min) to 5.15 in the UV/ @entity5568 and from 6.4 (t 0min) to 5.9 in the UV/ @entity3759 at the end of the experiments. The initial pH of the UV/ @entity8798 / @entity5568 experiments was adjusted to 5 and after the addition of @entity5568 the pH decreased to around 3 and remained in this range until the end of the treatments.

title: Removal of the anti- @entity5 drug @entity1499 from water by advanced oxidation processes: Aerobic biodegradation and XXXX studies after treatment.

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity1499 :: ('MESH:D008727', 'Chemical') :: ['Methotrexate']

answer: @entity137 :: (MESH:D064420,Disease) :: ['toxicity']


abstract: The alpha chain of the interleukin 2 receptor ( @entity2902 ; Tac) was targeted in clinical trials with @entity1619 using murine anti-Tac antibody. Of 19 @entity1 , a single individual achieved a durable complete remission. The mechanism of this action by murine anti-Tac has not been defined. We examined the hypothesis that the maintenance of the long-term response after treatment might be related to induction of a network of anti-idiotypic antibodies, as proposed in other @entity5 settings. In contrast to anti-Tac non-responders, the @entity1 was found to have produced a @entity1701 ( @entity1701 ) response, and specifically an anti-idiotypic (Ab2) response, that was readily detectable by standard assays 4 years after treatment. Using phage display antibody libraries, this response was shown to be monoclonal, consisting of a single IgG1,kappa antibody of moderate affinity. No evidence was found for anti-anti-idiotypic (Ab3) antibodies with reactivity for sTac, which might alternatively have maintained an autogenic human anti-Tac antibody response. An area of limited homology was noted between the Ab2 antibody and the @entity2902 in the domain of @entity1199 binding, but no binding of Ab2 to @entity1199 could be shown that might have reduced endogenous ligand ( @entity1199 ) concentrations. Similarly, no anti-anti-idiotypic (T3) T cell response was detected. Thus, we are unable to confirm features of idiotypy that could suggest a role in maintaining an anti- @entity5 response by anti-Tac antibody therapy.

title: Examination of a role for idiotypy in the disease remission of a long-term survivor of XXXX treated with anti-Tac antibody.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1619 :: ('MESH:D015458', 'Disease') :: ['adult T cell leukemia']

entities_list: @entity1701 :: ('MESH:D016736', 'Disease') :: ['HAMA', 'human anti-mouse antibody']

answer: @entity1619 :: (MESH:D015458,Disease) :: ['adult T cell leukemia']


abstract: AIMS: Increased @entity1002 ( @entity1002 ) is a common finding in cardiology. It is not known how often hereditary transthyretin-related @entity296 ( @entity52434 - @entity7366 ) is responsible for @entity1002 . Several therapeutic modalities for @entity52434 - @entity7366 are currently in clinical trials; thus, it is important to establish the prevalence of @entity20117 mutations ( @entity52434 ) and the clinical characteristics of the @entity1 with @entity52434 - @entity7366 . METHODS AND RESULTS: In a prospective multicentre, cross-sectional study, the @entity20117 gene was sequenced in 298 consecutive @entity1 diagnosed with increased @entity1002 in primary cardiology clinics in France. Among the included @entity1 , median (25-75th percentiles) age was 62 [50;74]; 74% were @entity1 ; 23% were of African origin; and 36% were in NYHA Class III-IV. Median @entity1002 was 18 (16-21) mm. Seventeen (5.7%; 95% confidence interval [CI]: [3.4;9.0]) @entity1 had @entity52434 of whom 15 (5.0%; 95% CI [2.9;8.2]) had @entity52434 - @entity7366 . The most frequent mutations were @entity68783 (n = 8), @entity57721 (n = 2), and @entity68784 (n = 2). All @entity52434 - @entity7366 @entity1 were older than 63 years with a median age of 74 [69;79]. Of the 15 @entity1 with @entity52434 - @entity7366 , 8 were of African descent while 7 were of European descent. In the African descendants, @entity52434 - @entity7366 median age was 74 [72;79] vs. 55 [46;65] years in non- @entity52434 - @entity7366 (P < 0.001). In an adjusted multivariate model, African origin, @entity16 , @entity923 , electrocardiogram (ECG) low voltage, and late @entity2287 enhancement (LGE) at cardiac-magnetic resonance imaging were all independently associated with @entity52434 - @entity7366 . CONCLUSION: Five per cent of @entity1 diagnosed with @entity1121 have @entity52434 - @entity7366 . Mutated transthyretin genetic screening is warranted in elderly subjects with increased @entity1002 , particularly, those of African descent with @entity16 , @entity923 , ECG low voltage, or LGE.

title: Prevalence and clinical phenotype of @entity296 in XXXX with increased @entity1002 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'men']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['familial amyloid cardiomyopathy']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathy']

entities_list: @entity57721 :: ('p|SUB|V|50|M', 'ProteinMutation') :: ['V50M']

entities_list: @entity2287 :: ('MESH:D005682', 'Chemical') :: ['gadolinium']

entities_list: @entity1121 :: ('MESH:D002312', 'Disease') :: ['hypertrophic cardiomyopathy']

entities_list: @entity923 :: ('MESH:D002349', 'Disease') :: ['carpal tunnel syndrome']

entities_list: @entity1002 :: ('MESH:D018487', 'Disease') :: ['LVWT', 'left ventricular wall thickness']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: There are few reports in the literature of the risks associated with second @entity5852 in @entity1 with @entity5030 ( @entity5030 ). We hypothesise that @entity5030 increases the risk of complications. AIMS: We sought to determine if @entity5030 is associated with a higher risk of @entity190 and blood transfusion at the time of dilation and evacuation (D_E). MATERIALS AND METHODS: The records of 612 consecutive @entity1 undergoing abortion at 15-24  weeks of gestation were reviewed. @entity1 characteristics, need for blood transfusion, estimated @entity190 (EBL) during the abortion and other complications were compared between @entity1 with and without ultrasound-documented @entity5030 . RESULTS: Eighty-seven of 612 (14.2%, 95% CI 11.5-17.2%) @entity1 had ultrasound-documented @entity5030 . The rate of blood transfusion was 3.4 and 1.3% in the group with @entity5030 and without @entity5030 , respectively (adjusted relative risk (RR  =  2.8, 95% CI 0.7-11.3). An estimated @entity190 of 500  cc or greater during the D_E procedure was observed in 12.6% of @entity1 in the @entity5030 group compared with 4.2% of @entity1 in the group without @entity5030 (adjusted RR 3.1, 95% CI 1.4-6.8, P  =  0.004). CONCLUSIONS: Second- @entity5852 in @entity1 with @entity5030 is associated with a higher risk of @entity190 of 500  cc or greater. Our study represents a larger sample size of @entity1 with @entity5030 undergoing second- @entity5852 than previously reported in the literature. @entity1 with @entity5030 may have a higher estimated @entity190 and may require access to blood transfusion.

title: Placenta praevia and the risk of adverse outcomes during second XXXX : A retrospective cohort study.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Women', 'Participant']

entities_list: @entity5030 :: ('MESH:D010923', 'Disease') :: ['placenta praevia', 'PP']

entities_list: @entity5852 :: ('MESH:D000031', 'Disease') :: ['trimester abortion']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

answer: @entity5852 :: (MESH:D000031,Disease) :: ['trimester abortion']


abstract: We report two cases of @entity249 treatment in couples where males suffered from @entity16179 ( @entity16179 ) and a total absence of motile sperm in the ejaculate. A total of three ICSI cycles was carried out. In all cycles, viable ejaculated or testicular spermatozoa were selected using the @entity4 ( @entity4 ) test. Case 1: In the first ICSI cycle total fertilization failure occurred after using ejaculated spermatozoa. In the following cycle testicular spermatozoa were used for ICSI, resulting in 75% fertilized oocytes and a pregnancy. Case 2: In the same ICSI cycle 50% of the oocytes were injected with ejaculated and 50% with testicular spermatozoa. The fertilization rates were 44 and 56% respectively and high quality embryos were achieved in both groups. One single embryo derived from testicular sperm was transferred with a resulting singleton pregnancy. In conclusion, testicular sperm for ICSI seem to have reliable fertilization capacity in @entity1 with @entity16179 , while ejaculated sperm, even if tested viable, seem more unpredictable. @entity4 test for selection of viable sperm for ICSI is recommended when ejaculated as well as testicular sperm are used for ICSI.

title: Different fertilization rates between immotile testicular spermatozoa and immotile ejaculated spermatozoa for ICSI in XXXX with @entity16179 : case reports.

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['HOS', 'hypo-osmotic swelling']

entities_list: @entity249 :: ('MESH:D007246', 'Disease') :: ['infertility']

entities_list: @entity16179 :: ('MESH:D007619', 'Disease') :: ["Kartagener's syndrome", 'KS']

answer: @entity1 :: (9606,Species) :: ['men']


abstract: OBJECTIVES: Inflammation is a well-established risk factor for the development of @entity453 ( @entity453 ) and @entity1187 ( @entity1187 ). However, less is known about its influence on the outcome of @entity1187 . The aim of this study was to determine if blood biomarkers of @entity32 were associated specifically with acute @entity583 ( @entity583 ) or @entity1459 ( @entity1459 ) in @entity1 with @entity1187 . DESIGN: Cross-sectional study. SETTING: @entity1 admitted to the coronary care unit, via the emergency room, at a central county hospital over a 4-year period (1992-1996). @entity1 : In a substudy of @entity299 ( @entity299 ) of 5292 @entity1 admitted to the coronary care unit, we identified 908 @entity1 aged 30-74 years, who at discharge had received the diagnosis of either @entity583 (527) or @entity1459 (381). MAIN OUTCOME MEASURES: @entity583 or @entity1459 , based on the diagnosis set at discharge from hospital. RESULTS: When adjusted for smoking, age, sex and duration of @entity662 , concentrations of plasma biomarkers of @entity32 (high-sensitivity C reactive protein>2 mg/L (OR=1.40 (1.00 to 1.96) and fibrinogen (p for trend=0.035)) analysed at admission were found to be associated with @entity583 over @entity1459 , in an event of @entity1187 . A strong significant association with @entity583 over @entity1459 was found for blood cell markers of @entity32 , that is, counts of neutrophils (p for trend<0.001), monocytes (p for trend<0.001) and thrombocytes (p for trend=0.021), while lymphocyte count showed no association. Interestingly, eosinophil count (p for trend=0.003) was found to be significantly lower in @entity1 with @entity583 compared to those with @entity1459 . CONCLUSIONS: Our results show that, in @entity1 with @entity1187 , the blood cell profile and degree of @entity32 at admission was associated with the outcome. Furthermore, our data suggest that a pre-existing low-grade @entity32 may dispose towards @entity583 over @entity1459 .

title: Influence of pre-existing @entity32 on the outcome of XXXX : a cross-sectional study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PARTICIPANTS']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity1187 :: ('MESH:D054058', 'Disease') :: ['ACS', 'acute coronary syndrome']

entities_list: @entity662 :: ('MESH:D002637', 'Disease') :: ['chest pain']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'MI']

entities_list: @entity1459 :: ('MESH:D000789', 'Disease') :: ['UA', 'unstable angina']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['Carlscrona Heart Attack Prognosis Study', 'CHAPS']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['CAD', 'coronary artery disease']

answer: @entity1187 :: (MESH:D054058,Disease) :: ['acute coronary syndrome']


abstract: A 75-year-old @entity1 presented with a 4-month history of a swollen and @entity158 penis. Computed tomography showed a round-shaped mass measuring 3   *   2   cm in the corpus cavernosum. Percutaneous drainage of the penile mass was carried out and a course of antibiotics was prescribed. Viral, fungal and selective bacterial cultures were negative. Total penectomy and urethroperineal @entity292 formation were carried out because of @entity546 . Histopathological diagnosis was xanthogranulomatous @entity738 of the corpus cavernosum. Before surgery, sonourethrography was carried out under general anesthesia. Sonourethrography is an infrequently used modality to observe the male urethra under urinary micturition or injection of saline. We previously reported modified sonourethrography with retrograde jelly injection. In the present case, sonourethrography successfully showed the damaged and deformed urethra including the @entity733 and @entity292 . Although xanthogranulomatous @entity738 is rare, the findings reported here showed the usefulness of sonourethrography for morphological evaluation of the male urethra.

title: Usefulness of sonourethrography for XXXX as a result of xanthogranulomatous @entity738 in the corpus cavernosum of an adult: A case report.

entities_list: @entity738 :: ('MESH:D006099', 'Disease') :: ['granuloma']

entities_list: @entity733 :: ('MESH:D000038', 'Disease') :: ['abscess cavity']

entities_list: @entity546 :: ('MESH:D004414', 'Disease') :: ['penile pain']

answer: @entity546 :: (MESH:D004414,Disease) :: ['penile abscess']


abstract: BACKGROUND: Long-distance axonal growth relies on the precise interplay of guidance cues and cell adhesion molecules. While guidance cues provide positional and directional information for the advancing growth cone, cell adhesion molecules are essential in enabling axonal advancement. Such a @entity734 on adhesion as well as guidance molecules can be well observed in dorsal commissural interneurons, which follow a highly stereotypical growth and guidance pattern. The mechanisms and molecules involved in the attraction and outgrowth towards the ventral midline, the axon crossing towards the contralateral side, the rostral turning after midline crossing as well as the guidance along the @entity2270 have been intensely studied. However, little is known about molecules that provide the basis for commissural axon growth along the anterior-posterior @entity2270 . RESULTS: @entity45255 , a recently discovered cell adhesion molecule of the IgCAM superfamily, is highly expressed in dorsolaterally located ( @entity70168 ) spinal interneurons. Functional studies inactivating @entity45255 by RNA interference (RNAi) or function-blocking antibodies demonstrate that either treatment results in a lack of commissural axon growth along the @entity2270 . Moreover, results from RNAi experiments targeting the contralateral side together with binding studies suggest that homophilic @entity45255 interactions between ipsilaterally projecting axons and post-crossing commissural axons may be the basis of axonal growth along the @entity2270 . CONCLUSIONS: Directed axonal growth of dorsal commissural interneurons requires an elaborate mixture of instructive (guidance) and permissive (outgrowth supporting) molecules. While Wnt and Sonic hedgehog (Shh) signalling pathways have been shown to specify the growth direction of post-crossing commissural axons, our study now provides evidence that homophilic @entity45255 interactions are essential for axonal extension along the @entity2270 . Interestingly, so far each part of the complex axonal trajectory of commissural axons uses its own set of guidance and growth-promoting molecules, possibly explaining why such a high number of molecules influencing the growth pattern of commissural interneurons has been identified.

title: Rostral growth of commissural axons requires the cell adhesion molecule XXXX .

entities_list: @entity2270 :: ('MESH:C566610', 'Disease') :: ['axis', 'longitudinal axis']

entities_list: @entity734 :: ('MESH:D019966', 'Disease') :: ['dependence']

answer: @entity45255 :: (161357,Gene) :: ['MDGA2']


abstract: The nuclear factor of activated T-cells (NFAT) c1 has been shown to be essential for @entity141 -dependent upregulation of @entity9740 ( @entity9740 ) I/b expression during skeletal muscle fiber type transformation. Here, we report activation of @entity3962 in @entity141 -ionophore-treated C2C12 myotubes and electrostimulated soleus muscle. Activated @entity1366 enhanced @entity9889 -dependent upregulation of a -2.4 kb MyHCI/b promoter construct without affecting subcellular localization of endogenous @entity9889 . Instead, @entity1366 -augmented phosphorylation of transcriptional coactivator @entity3493 , promoted its recruitment to @entity9889 and increased @entity9889 -DNA binding to a NFAT site of the MyHCI/b promoter. In line, inhibition of @entity1366 signaling abolished the effects of @entity3493 . Comparison between wild-type @entity3493 and an acetyltransferase-deficient mutant (p300DY) indicated increased @entity9889 -DNA binding as a consequence of @entity3493 -mediated acetylation of @entity9889 . Activation of the MyHCI/b promoter by @entity3493 depends on two conserved acetylation sites in @entity9889 , which affect DNA binding and transcriptional stimulation. @entity9889 acetylation occurred in @entity141 -ionophore treated C2C12 myotubes or electrostimulated soleus. Finally, endogenous MyHCI/b gene expression in C2C12 myotubes was strongly inhibited by p300DY and a mutant deficient in ERK phosphorylation sites. In conclusion, @entity1366 -mediated phosphorylation of @entity3493 is crucial for enhancing @entity9889 transactivation function by acetylation, which is essential for @entity141 -induced MyHCI/b expression.

title: Extracellular signal-regulated kinase 1/2-mediated phosphorylation of XXXX enhances @entity9740 I/beta gene expression via acetylation of nuclear factor of activated T cells c1.

entities_list: @entity9740 :: ('4624', 'Gene') :: ['myosin heavy chain', 'MyHC']

entities_list: @entity3962 :: ('5594;5595', 'Gene') :: ['extracellular signal-regulated kinase (ERK) 1/2']

answer: @entity3493 :: (2033,Gene) :: ['p300']


abstract: BACKGROUND: The Obesity Surgery Mortality Risk Score (OS- @entity7748 ) was developed using data from 1995 to 2004; it has yet to be validated for more recent @entity1 in integrated delivery system settings. The objective of this study was to validate the OS- @entity7748 using data from electronic health records in a distributed data network. METHODS: We conducted a retrospective cohort study of 3,817 adults who underwent an open (21.4%) or laparoscopic (78.6%) gastric bypass surgery between 2005 and 2007 in the Scalable Partnering Network. Our main outcome was all-cause mortality during the 90 days after surgery. We scored @entity1 ' risk of mortality by adding characteristics according to the OS- @entity7748 (i.e., 1 point for each predictor). RESULTS: Sixteen of 3,817 (0.42/100; 95% CI, .24-.68) @entity1 died within 90 days. The OS- @entity7748 discriminated low-risk and high-risk @entity1 effectively: low-risk (2 of 1,654 @entity1 ; .12 @entity204 /100 @entity1 ), intermediate-risk (10 of 2,008 @entity1 ; .50 @entity204 /100 @entity1 ), and high-risk (4 of 155 @entity1 ; 2.58 @entity204 /100 @entity1 ). High-risk @entity1 were 21.3 times more likely to die in the first 90 days after surgery than low-risk @entity1 (risk ratio = 21.3; 95% CI, 3.9-115.6). CONCLUSION: In these 10 U.S. healthcare delivery systems, the OS- @entity7748 appears valid-albeit with the caveat that we observed a small number of @entity204 . The OS- @entity7748 appears useful for identifying the small fraction of @entity1 at high risk for 90-day mortality after open and laparoscopic RYGB.

title: Predicting 90-day mortality after bariatric surgery: an independent, external validation of the OS- XXXX prognostic risk score.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

answer: @entity7748 :: (MESH:D008556,Disease) :: ['MRS']


abstract: A decline in age-adjusted ischemic @entity65 mortality has been observed in the United States during the past two decades. Among the leading explanatory hypotheses is improvement in the major known risk factors for @entity299 and @entity64 in the general population, specifically @entity101 , smoking, and lipid levels. To better understand risk factor trends, the @entity299 ( @entity299 ) began systematic risk factor surveys of the Minneapolis-St Paul population in 1980, (population 1.99 million). The metropolitan area was divided into 704 subareas (clusters) of approx. 1000 households each, utilizing geographic boundaries. In a two-stage cluster sampling technique, 40 subareas were randomly chosen and mapped. Approximately 8.75% of households were chosen from each subarea and selected residents age 25-74 years invited to participate. A total 4451 individuals participated in 1980-82. The response rate for a home interview was 81.9 and 84.4% for a subsequent survey center visit, producing an overall response of 69.1%. The age and sociodemographic characteristics of the survey @entity1 were similar to those found in the 1980 census. The prevalence of @entity101 was 18.3% in this population with 76.0% taking medications and 65.0% controlled. Total @entity165 and HDL- @entity165 levels demonstrated age and sex differences similar to those reported elsewhere. Current smoking of cigarettes was equally prevalent in @entity1 (34.5%) and @entity1 (33.5%) although more @entity1 were former smokers (35.2 vs 20.6%). @entity299 with the National HANES II data (1976-80) indicates lower regular cigarette smoking among Minnesota males, with similar rates in females. Minnesota residents had better control of @entity101 .

title: Population risk of XXXX : the @entity299 .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'men']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['high blood pressure', 'hypertension']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['MHS', 'Minnesota Heart Survey', 'Comparison of the MHS', 'heart attack']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity65 :: (MESH:D002318,Disease) :: ['cardiovascular disease']


abstract: UNASSIGNED: The occurrence of a kidney transplant @entity5 is a rare but serious issue with a double risk: the return to dialysis and the development of @entity5 . Publications on this topic are mainly case reports. The purpose of this review was to report an exhaustive literature review of functional graft @entity1358 to highlight the impact of @entity5 on the renal graft outcomes. 201 de novo @entity703 in functional renal grafts from 69 publications were included. Incidence was estimated at 0.18%. Graft @entity5 were mostly asymptomatic (85.9%). Whatever the discovery circumstances of graft @entity5 , they were mostly documented by graft ultrasounds supplemented by CT-scanning or MR imaging. Nephron sparing surgery (95 @entity1 ) was the first treatment performed followed by radiofrequency ablation (38 @entity1 ) and cryotherapy (10 @entity1 ). The most common @entity5 graft histology was @entity1358 (46.4%), followed by @entity1377 (43.7%). Specific mortality was 2.9% with 6 deaths. Renal graft cell @entity189 is a rare pathology with a low specific @entity204 . When possible, conservative treatment should be the first choice.

title: XXXX in functional renal graft: Toward ablative treatments.

entities_list: @entity1377 :: ('MESH:D002291', 'Disease') :: ['papillary carcinoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'metastatic cancer', 'tumors']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinomas', 'clear cell carcinoma']

entities_list: @entity703 :: ('MESH:D007680', 'Disease') :: ['renal carcinomas']

answer: @entity1358 :: (MESH:D002292,Disease) :: ['Renal cell carcinoma']


abstract: The objective of this study was to determine the immunoexpression pattern of the mitogen-activated protein kinase (MAPK), and related signalling proteins [ @entity7131 ( @entity7131 ), phospholipase Cgamma (PLCgamma)], in @entity463 multi-forme, and to investigate their prognostic value. @entity982 -embedded biopsy samples from 26 @entity1 [13 @entity1 with long-term survival (LTS; N=13; median 28 months, range 13-76 months), and, for comparison, 13 @entity1 with short-term survival (STS; N=13; median 7 months, range 1-12 months)] were investigated for the immunoexpression of MAPK, the activated pMAPK, @entity7131 , PLCgamma, @entity470 , and @entity983 . Additionally, the @entity1758 proliferation index was determined. The immunoexpression pattern were related to clinical data, including analysis of their prognostic value using the Cox-proportional hazard model. No significant differences were found between STS and LTS in terms of age, Karnofsky performance status, and treatment. Whereas @entity470 expression did not differ between STS and LTS and does not influence survival, expression of MAPK and activated pMAPK was significantly correlated with survival time. The percentage of pMAPK expressing cells correlated strongly with the percentage of @entity1758 positive cells. Furthermore, survival in @entity1 with @entity5 expressing @entity7131 or PLCgamma was significantly shorter. No differences were found for @entity983 expression. Our findings indicate that the MAPK pathway is correlated with proliferation in @entity11 , and that @entity1 subgroups exist, in which expression of MAPK-related signalling proteins ( @entity7131 , PLCgamma) is associated with poorer prognosis. These @entity1 subgroups may benefit from additional chemotherapeutic agents which specifically inhibit these signalling proteins.

title: Prognostic relevance of MAPK expression in XXXX multiforme.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']

entities_list: @entity7131 :: ('MESH:D020151', 'Disease') :: ['protein kinase C', 'PKC']

entities_list: @entity11 :: ('MESH:D005910', 'Disease') :: ['gliomas']

entities_list: @entity982 :: ('MESH:D010232', 'Chemical') :: ['Paraffin']

entities_list: @entity463 :: ('MESH:D005909', 'Disease') :: ['glioblastoma']

answer: @entity463 :: (MESH:D005909,Disease) :: ['glioblastoma']


abstract: UNASSIGNED: Adeno-associated viruses (AAVs) have become powerful tools in neuroscience for both basic research and potential therapeutic use. They have become especially important tools for optogenetic experiments based on their ability to achieve transgene expression in postmitotic neurons with regional selectivity. With the use of appropriate promoter elements they can achieve cellular specificity as well. One population of neurons that plays a central role in @entity1 neurodegenerative and @entity146 diseases are the @entity935 neurons of the midbrain. To study these neurons in vivo with advanced techniques it would be highly advantageous to characterize an appropriate specific promoter. To this end we have characterized a 2.5-kb sequence of the @entity35 @entity4149 hydroxylase ( @entity68883 ) promoter. The @entity68883 (2.5) promoter induced expression of the fluorescent reporter protein mCherry in SN @entity935 neurons. Although it showed excellent specificity in cortex and striatum, where no reporter expression was observed, in the SN region many neurons expressed reporter but not @entity68883 . We show that some of the @entity68883 negativity is due to the suppression of its expression by the transgene. We conclude that @entity68883 (2.5) does preferentially label @entity935 neurons but its specificity is not complete within the substantia nigra and caution must be used.

title: A quantitative evaluation of a 2.5-kb @entity35 @entity4149 hydroxylase promoter to target expression in ventral mesencephalic XXXX neurons in vivo.

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric']

entities_list: @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine']

answer: @entity935 :: (MESH:D004298,Chemical) :: ['dopamine']


abstract: BACKGROUND/AIMS: To examine the reproducibility of lesion dimensions of the @entity989 ( @entity989 ) in neovascular @entity1020 ( @entity1020 ) with polarisation-sensitive optical coherence tomography (PS- @entity6653 ), specifically imaging the @entity989 . METHODS: Twenty-six @entity1 (28 eyes) with @entity1020 were included in this study, and examined by a PS- @entity6653 prototype. Each @entity1 was scanned five times at a 1-day visit. The PS- @entity6653 B-scan located closest to the macular centre presenting with @entity989 @entity194 was identified, and the longitudinal diameter of the lesion was quantified manually using AutoCAD 2008. This procedure was followed for the identical B-scan position in all five scans per eye and @entity1 . Reproducibility of qualitative changes in PS- @entity6653 was evaluated. Interobserver variability was assessed. Results were compared with intensity-based spectral-domain @entity6653 (SD- @entity6653 ) imaging. RESULTS: Mean variability of all @entity194 lesion dimensions was 0.10   mm (SD  =0.06   mm). Coefficient of variation (SD  /mean) was 0.06 on average (SD  =0.03). Interobserver variability assessment showed a mean difference of 0.02   mm across all @entity1 regarding @entity989 lesion size evaluation (paired t test: p=0.38). Spearman correlation coefficient was r=0.98, p<0.001. Results revealed a good overall reproducibility of    90%. PS- @entity6653 specifically detected the @entity989 in all eyes compared with conventional intensity-based SD- @entity6653 that was not capable to clearly identify @entity989 @entity194 in 25 eyes (89.3%, p<0.01). CONCLUSIONS: PS- @entity6653 offers good reproducibility of @entity989 @entity194 assessment in @entity1020 , and may be suitable for precise @entity989 evaluation in clinical practice. PS- @entity6653 unambiguously identifies @entity989 changes in @entity3193 compared with intensity-based SD- @entity6653 that does not identify the @entity989 status reliably.

title: Polarisation-sensitive @entity6653 is useful for evaluating retinal pigment epithelial lesions in XXXX with @entity1020 .

entities_list: @entity3193 :: ('MESH:D015862', 'Disease') :: ['choroidal neovascularisation']

entities_list: @entity989 :: ('MESH:D012164', 'Disease') :: ['retinal pigment epithelium', 'RPE']

entities_list: @entity1020 :: ('MESH:D008268', 'Disease') :: ['neovascular AMD', 'AMD', 'age-related macular degeneration']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: The significance of cardiac troponin I (TnI) levels in @entity1 with acute @entity385 remains unclear. METHODS: Data were prospectively collected on 1718 @entity1 with acute @entity385 (2009-2010). @entity1 with positive TnI (peak TnI >= 0.1  g/L) were assigned to the @entity583 ( @entity583 ) group if they met diagnostic criteria. The remaining @entity1 with positive TnI were assigned to the no- @entity583 group. @entity1 were followed up for 1.4    1.1 years. Primary outcome was inhospital and long-term all-cause mortality. RESULTS: Positive TnI was present in 309 @entity1 (18%), 119 of whom (39%) were classified as having @entity583 . Positive TnI was independently associated with older age, @entity101 , smoking, peripheral @entity455 , @entity712 , higher systolic blood pressure, higher serum @entity1011 , and lower heart rate (P < .01). @entity1 with @entity583 had the highest inpatient mortality (P < .001) and the lowest survival rate by Kaplan-Meier analysis (P < .0001). Peak TnI greater than or equal to 0.5  g/L, particularly if satisfying criteria for @entity583 , was independently associated with long-term mortality (P < .0001); peak TnI less than 0.5  g/L alone was not when adjusted for covariates. CONCLUSION: Positive TnI greater than or equal to 0.5  g/L in @entity1 with acute @entity385 was independently associated with worse outcomes. @entity1 with diagnosis of @entity583 represent a particularly high-risk subgroup.

title: The prognostic significance of troponin I elevation in acute XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['arterial disease']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'MI']

entities_list: @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']

answer: @entity385 :: (MESH:D002544,Disease) :: ['ischemic stroke']


abstract: OBJECTIVE: To estimate the cost-effectiveness of three @entity5626 ( @entity25928 , @entity11794 , and @entity1331 ) and generic @entity2380 in the treatment of nonneutropenic adult @entity1 with @entity4963 and/or @entity3 in intensive care units in Spain. MATERIALS AND METHODS: A decision-tree model was applied. The success and safety (hepatic and renal adverse effects) of first-line treatments were obtained from meta-analyses and systematic reviews of clinical trials. In the case of failure, a second-line treatment (liposomal @entity2379 after the @entity5626 , or one of the @entity5626 after @entity2380 ) was administered. The duration of the treatments (14 days total) was established by a panel of clinical experts using the Delphi method and according to @entity166 Society of America guidelines. The cost of the medications and renal @entity137 were considered. Deterministic and probabilistic sensitivity analysis using Monte Carlo simulations were carried out. RESULTS: The total cost of the treatment of @entity4963 and/or @entity3 with @entity25928 , @entity11794 , @entity1331 , and @entity2380 was    5,483,    5,968,    6,231, and    2,088, respectively. @entity25928 was the dominant treatment (more effective, less expensive) compared to @entity1331 and @entity11794 . The cost of achieving one more @entity1 successfully treated with @entity25928 , @entity11794 , and @entity1331 compared to @entity2380 was    17,199,    23,962, and    27,339, respectively. The result remained stable, despite modification of the duration of the first-line and second-line treatments, as well as most of the dosing regimens. The probabilistic analysis also remained stable. CONCLUSION: In accordance with this economic study, @entity25928 would produce savings and would be the dominant treatment compared with @entity1331 and @entity11794 in nonneutropenic adult @entity1 with @entity4963 and/or @entity3 in intensive care units in Spain.

title: Cost-effectiveness of three @entity5626 and XXXX in the treatment of @entity4963 and/or @entity3 in nonneutropenic adult @entity1 .

entities_list: @entity1331 :: ('MESH:C121905', 'Chemical') :: ['micafungin']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity25928 :: ('MESH:C102786', 'Chemical') :: ['anidulafungin', 'Anidulafungin']

entities_list: @entity2379 :: ('MESH:D000666', 'Chemical') :: ['amphotericin B']

entities_list: @entity2380 :: ('MESH:D015725', 'Chemical') :: ['fluconazole']

entities_list: @entity4963 :: ('MESH:D058387', 'Disease') :: ['candidemia']

entities_list: @entity5626 :: ('MESH:D054714', 'Chemical') :: ['echinocandins']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['invasive candidiasis']

entities_list: @entity166 :: ('MESH:D003141', 'Disease') :: ['Infectious Diseases']

entities_list: @entity11794 :: ('MESH:C105417', 'Chemical') :: ['caspofungin']

answer: @entity2380 :: (MESH:D015725,Chemical) :: ['fluconazole']


abstract: An HPLC method was developed for the determination of @entity50252 (NHDC) in foods. A solid sample was extracted with @entity1042 . The extract was evaporated and the residue was dissolved in @entity1042 -water (2:8) mixture. In the case of fluid sample, the sample solution was prepared by dilution with @entity1042 -water (2:8) mixture. The sample solution was cleaned up on a C18 cartridge. The cartridge was washed with water and @entity1042 -water (3:7) mixture, and NHDC was eluted with @entity1042 -water (7:3) mixture. NHDC in the eluate was separated on an ODS column and determined with a UV detector (282 nm). The identity of NHDC in foods was confirmed by means of HPLC with a photodiode-array detector. The recoveries of NHDC added to various kinds of foods were 75.2-134%. The determination limit of NHDC was 1 microgram/g.

title: [Determination of XXXX in foods].

entities_list: @entity1042 :: ('MESH:D000432', 'Chemical') :: ['methanol']

entities_list: @entity50252 :: ('MESH:C013613', 'Chemical') :: ['neohesperidin dihydrochalcone']

answer: @entity50252 :: (MESH:C013613,Chemical) :: ['neohesperidin dihydrochalcone']


abstract: @entity15 ( @entity15 ) may be associated with @entity73 . However, emotion recognition mediated by bodily postures has never been examined in these @entity1 . Moreover, several studies have suggested a relation between emotion @entity73 and alexithymia. This is in line with the idea that the ability to recognize emotions requires the individuals to be able to understand their own emotions. Despite a deficit in emotion recognition has been observed in @entity15 @entity1 , the association between @entity73 has received little attention. The aim of this study was, first, to investigate @entity15 @entity1 's abilities to recognize emotions mediated by both facial and bodily expressions and, second, to examine whether any observed @entity51 recognition could be explained by the presence of alexithymia. Thirty @entity1 with @entity15 and 30 healthy matched controls performed experimental tasks assessing emotion discrimination and recognition of facial expressions and bodily postures. Moreover, they completed questionnaires evaluating alexithymia, @entity308 , and fatigue. First, facial emotion recognition and, to a lesser extent, bodily emotion recognition can be impaired in @entity15 @entity1 . In particular, @entity1 with higher disability showed an @entity73 compared with @entity1 with @entity717 and controls. Second, their deficit in emotion recognition was not predicted by alexithymia. Instead, the disease's characteristics and the performance on some cognitive tasks significantly correlated with emotion recognition. @entity73 recognition is a cognitive signature of @entity15 that is not dependent on alexithymia. (JINS, 2014, 19, 1-11).

title: Facial and bodily emotion recognition in XXXX : the role of alexithymia and other characteristics of the disease.

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['impairment in emotion recognition', 'recognition impairments', 'impaired emotion recognition and alexithymia', 'Impaired facial emotion', 'impaired perception of facial emotions']

entities_list: @entity51 :: ('MESH:D009461', 'Disease') :: ['deficits in emotions']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['lower disability']

entities_list: @entity15 :: ('MESH:D009103', 'Disease') :: ['Multiple sclerosis', 'MS']

answer: @entity15 :: (MESH:D009103,Disease) :: ['multiple sclerosis']


abstract: BACKGROUND: Treatment verification and contact elicitation are core approaches used to control the spread of @entity2953 ( @entity2953 ). Methodology adapted from the @entity645 care continuum is presented as an evaluation and communication tool for STD control activities. METHODS: Sexually transmitted disease surveillance and program data for Los Angeles County in 2013 were used to construct a 2-part continuum to examine syphilis (all stages) and @entity2954 outcomes among index @entity1 and elicited contacts. The Index Case Continuum (Part 1) assesses the proportion of @entity1 who were treated, assigned for interview, interviewed, and provided name and locating information for at least 1 contact. The Elicited Contact Continuum (Part 2) assesses the proportion of contacts who were located, interviewed, and treated. RESULTS: Among 3668 @entity1 with syphilis, 97% (n = 3556) were treated, 72% (n = 2633) were interviewed, and 25% (n = 920) provided name and locating information for at least 1 contact. The corresponding numbers for 12,541 @entity2954 cases were 95% (n = 11,936), 45% (n = 5633), and 16% (1944), respectively. Among the 1392 contacts elicited from syphilis cases, 53% (n = 735) were either interviewed or determined to not need an interview and 43% (n = 595) were treated. The corresponding numbers for the 2323 contacts elicited from @entity2954 cases were 53% (n = 1221) and 46% (n = 1075), respectively. CONCLUSIONS: Adaptation of the @entity645 continuum is a useful tool for evaluating treatment verification and contact elicitation activities. In Los Angeles County, this approach revealed significant drop-offs in the proportion of index cases naming contacts and in the proportion of contacts who are interviewed and treated.

title: Adaptation of the @entity645 Care Continuum as a Method for Evaluating Syphilis and XXXX Control Activities in Los Angeles County.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2954 :: ('MESH:D006069', 'Disease') :: ['gonorrhea']

entities_list: @entity2953 :: ('MESH:D012749', 'Disease') :: ['STDs', 'sexually transmitted diseases']

answer: @entity2954 :: (MESH:D006069,Disease) :: ['Gonorrhea Disease']


abstract: @entity75 of the glenohumeral joint in early stages and in younger @entity1 are an important problem and present a challenge during clinical decision making. Although prosthetic arthroplasty remains the gold standard for treatment in later stages of the disease, alternatives are desirable in the early stages and in young @entity1 . The purposes of this study are to evaluate the results of arthroscopic debridement and capsular release in @entity1 with grade IV @entity75 of the glenohumeral joint and to determine the factors associated with their success. Sixty-one @entity1 with grade IV @entity75 of the glenohumeral articular surfaces were treated with arthroscopic debridement, with or without arthroscopic capsular release. Standardized data collection was performed at the initial office visit and at the time of final follow-up. Overall outcome was analyzed with regard to @entity1 ' self-assessment of @entity158 , function, improvement, satisfaction, and duration of @entity158 relief. Forty-five of the @entity1 had a minimum follow-up of 2 years. Time-to-event analysis was used to evaluate the duration of @entity158 relief. The mean @entity1 satisfaction score (0 = not satisfied; 10 = completely satisfied) improved from 0.67 preoperatively to 6.28 at final follow-up (P <.0001), with 87% of @entity1 indicating that they would have the surgery again. Although workers' compensation @entity1 obtained inferior results, significant improvement in @entity158 and function was obtained in 88% of all @entity1 (P <.0001). Most @entity1 noted the onset of @entity158 relief within 5 weeks of surgery and obtained a duration of @entity158 relief of 28 months or greater (P <.05). The addition of concomitant procedures, such as acromioplasty, distal clavicle resection, labral debridement, or labral repair, did not have a negative impact on the functional results after arthroscopic debridement and capsular release. In well-selected @entity1 with grade IV @entity75 of the glenohumeral joint, significant improvements in @entity158 relief and function follow arthroscopic debridement of the glenohumeral joint. Arthroscopic capsular release can be added in @entity1 with a loss of passive arcs of shoulder motion. @entity75 greater than 2 cm(2) appear to be associated with return of @entity158 and failure of this procedure.

title: Non-prosthetic management of grade IV XXXX of the glenohumeral joint.

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['osteochondral lesions', 'Osteochondral lesions']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

answer: @entity75 :: (MESH:D001927,Disease) :: ['osteochondral lesions']


abstract: @entity157 ( @entity157 ) is the fifth most common @entity5 worldwide and the third most common @entity5 in Asia. @entity157 has heterogeneous etiologic and molecular profiles and a varied response to therapeutics. The high recurrence rate and curtailed survival in this @entity5 are attributed to its resistance to therapy. The ultimate goal is to develop a more effective personalized therapeutic strategy for @entity157 , but the first step is to develop a system for classifying the disease on the basis of molecular biomarkers. To that end, we performed mRNA and microRNA (miRNA) expression profiling in 100 @entity157 tissues. Clustering analysis of informative genes identified two robust subtypes, which were validated by an independent dataset. The subtype characterized by a @entity5 stem cell-like signature was clinically aggressive and associated with poor survival. Integrated analysis of miRNA and mRNA expression in this subtype showed that @entity13823 was expressed at a significantly lower level in these @entity5 than in the other subtype. @entity13823 has been shown to directly suppress the expression of @entity15703 ( @entity15703 ), a key receptor in the signaling pathway of the bone morphogenetic proteins (BMPs), which regulate many stem cell markers as well as the clinically important cytokine @entity687 ( @entity687 ). Increased expression of @entity15703 and its downstream genes @entity5960 , @entity11707 , @entity5399 , and @entity687 was associated with shorter survival in a larger cohort of 227 @entity157 cases. Introduction of @entity13823 resulted in suppressed @entity5 phenotypes both in vitro and in vivo. CONCLUSION: We identified a clinically aggressive stem cell-like subtype of @entity157 that is characterized by an @entity13823 - @entity15703 - @entity6861 -Wnt circuit. We propose that @entity13823 may serve as a prognostic biomarker and therapeutic target for this subtype of @entity157 .

title: Regulatory XXXX - @entity15703 / @entity6861 circuit defines a @entity5 .

entities_list: @entity15703 :: ('90', 'Gene') :: ['activin A receptor type 1', 'ACVR1']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'malignancy', 'tumors']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'Hepatocellular carcinoma']

answer: @entity13823 :: (406940,Gene) :: ['MiR-148a']


abstract: BACKGROUND: Oncology nurses play a crucial role in @entity5 management and must be highly informed to ensure their effective practice in the @entity5 setting. The aim of this study was to determine the baseline level of knowledge and attitudes of oncology nurses regarding @entity5 management. MATERIALS AND METHODS: A cross-sectional survey research design was employed. The sample comprised 58 @entity5 nurses working in Shahid Sadoughi hospital, Yazd, Iran. The ''Nurses Knowledge and Attitudes Survey Regarding @entity158 '' (NKAS) tool and a demographic form were utilized to ascertain the knowledge and attitudes of oncology nurses working in oncology settings. RESULTS: The average correct response rate for oncology nurses was 66.6%, ranging from 12.1% to 94.8%. The nurses mean score on the knowledge and attitudes survey regarding @entity158 management was 28.5%. Results revealed that the mean percentage score overall was 65.7%. Only 8.6% of nurse @entity1 obtained a passing score of 75% or greater. Widespread knowledge deficits and poor attitudes were noted in this study, particularly regard pharmacological management of @entity158 . CONCLUSIONS: The present study provides important information about knowledge deficits in @entity158 management among oncology nurses and limited training regarding @entity158 management. Our results support the universal concern of inadequate knowledge and attitudes of nurses regarding @entity5 . It is suggested educational and quality improvement initiatives in @entity158 management could enhance nurses knowledge in the area of @entity158 and possibly improve practice.

title: Oncology Nurses Knowledge and Attitudes Regarding XXXX Management.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'cancer pain']

entities_list: @entity1 :: ('9606', 'Species') :: ['participants']

answer: @entity5 :: (MESH:D009369,Disease) :: ['Cancer Pain']


abstract: BACKGROUND: Platelet activation and consumption are common in @entity3124 @entity1 and are associated with poorer prognosis. Mean platelet volume is a simple surrogate for platelet activation, with higher @entity6688 being associated with worse clinical condition on a large array of clinical diagnoses. We therefore aimed to investigate associations between changes in platelet count and mean platelet volume ( @entity6688 ) with prognosis and inflammatory cytokine values in @entity3124 @entity1 . METHODS: This study prospectively included 84 @entity3124 @entity1 . @entity1 were stratified into four groups according to proportional changes in @entity6688 (  MPV24h) and platelet count (  Plat24h) in the first 24  hours after admission. Mortality between groups was compared using the    (2) test. Logistic regression was performed using hospital mortality as outcome and Simplified Acute Physiology Score ( @entity25079 ),   @entity3479 24h and   MPV24h as covariates. Concentrations of the following inflammatory mediators were measured using Miliplex   technology: @entity1356 , @entity650 , @entity687 , @entity688 , epidermal growth factor, vascular endothelial growth factor, @entity310 and @entity686 . Cytokine concentrations were compared between groups using the Kruskal-Wallis test with Bonferroni correction. RESULTS: @entity1 in whom @entity6688 increased and platelet count decreased had higher mortality rates (46%). According to logistic regression,   MPV24h was independently associated with increased mortality (OR 1.28 per 1% increase; 95% CI 1.08 to 1.48). No strong associations between inflammatory mediators and changes in @entity6688 and platelet count were found. CONCLUSION: An increase in @entity6688 after admission to an ICU is independently associated with higher hospital mortality.

title: An increase in mean platelet volume after admission is associated with higher mortality in @entity3124 XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity3124 :: ('MESH:D016638', 'Disease') :: ['critically ill']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: @entity1125 ( @entity1125 ) is a rare and lethal disease with few therapeutic options. Preclinical data suggest that the @entity470 ( @entity470 ) pathway could be involved in its progression. METHODS: This open-label, randomized phase 2 trial recruited chemotherapy-naive @entity1 with advanced @entity1125 displaying a wild-type (WT) @entity984 status. @entity1 were randomized to @entity136 (1000   mg/m(2) ) and @entity901 (100   mg/m(2) ) with (arm A) or without (arm B) panitumumab (6   mg/kg) for up to 12 cycles. The primary endpoint was progression-free survival (PFS) analyzed in an intention-to-treat fashion. RESULTS: Eighty-nine @entity1 (45 in arm A and 44 in arm B) were enrolled between June 2010 and September 2013. After a median follow-up of 10.1 months, the median PFS was 5.3 months (95% confidence interval, 3.3-7.2 months) in arm A and 4.4 months (95% confidence interval, 2.6-6.2 months) in arm B (P   =   .27). No survival differences were observed: the median overall survival was 9.9 months in arm A and 10.2 months in arm B (P   =   .42). In a subgroup analysis, no differences in PFS according to the site of the primary @entity5 were observed; @entity1 with @entity1419 treated with panitumumab may have had a survival benefit in comparison with the control group (15.1 vs 11.8 months, P   =   .13). As for safety, @entity137 was the main adverse event in arm A (80% of the @entity1 ). A higher incidence of @entity294 (55.5% vs 31.8%), @entity33 (22.2% vs 13.6%), and @entity1142 (24.4% vs 15.9%) was seen in arm A. CONCLUSIONS: These results confirm the marginal role of anti- @entity470 therapy even for WT @entity984 -selected @entity1125 . @entity5 2016;122:574-581.    2015 American @entity5 Society.

title: Panitumumab in combination with XXXX and @entity901 does not prolong survival in wild-type @entity984 advanced @entity1125 : A randomized phase 2 trial (Vecti-BIL study).

entities_list: @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['skin toxicity']

entities_list: @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Cancer']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis']

entities_list: @entity1419 :: ('MESH:C535533', 'Disease') :: ['intrahepatic cholangiocarcinoma']

entities_list: @entity1142 :: ('MESH:D003248', 'Disease') :: ['constipation']

entities_list: @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']

entities_list: @entity1125 :: ('MESH:D001661', 'Disease') :: ['BTC', 'Biliary tract cancer']

answer: @entity136 :: (MESH:C056507,Chemical) :: ['gemcitabine']


abstract: PURPOSE: To analyze the differences between the intensity-modulated radiotherapy (IMRT), single/partial-arc volumetric modulated arc therapy (SA/PA-VMAT) techniques in treatment planning for locally advanced @entity2 . MATERIALS AND METHODS: 12 @entity1 were retrospectively studied. In each @entity1 's case, several parameters were analyzed based on the dose-volume histograms (DVH) of the IMRT, SA/PA-VMAT plans respectively. Also, each plan was delivered to a phantom for time comparison. RESULTS: The SA-VMAT plans showed the superior target dose coverage, although the minimum/mean/maximum doses to the target were similar. For the total and contralateral lungs, the higher V5/10, lower V20/30 and @entity358 ( @entity358 ) were observed in the SA/PA-VMAT plans (p < 0.05, respectively). The PA-VMAT technique improves the dose sparing (V20, V30 and @entity358 ) of the controlateral lung more notably, comparing to those parameters of the IMRT and SA-VMAT plans respectively. The delivered monitor units (MUs) and treatment times were reduced significantly with VMAT plans, especially PA-VMAT plans (for MUs: mean 458.3 vs. 439.2 vs. 435.7 MUs, p < 0.05 and for treatment time: mean 13.7 vs. 10.6 vs. 6.4 minutes, p < 0.01). CONCLUSIONS: The SA-VMAT technique achieves highly conformal dose distribution to the target. Comparing to the IMRT plans, the higher V5/10, lower V20/30 and @entity358 were observed in the total and contralateral lungs in the VMAT plans, especially in the PA-VMAT plans. The SA/PA-VMAT plans also reduced treatment time with more efficient dose delivering. But the clinical benefit of the VMAT technique for locally advanced @entity2 needs further investigations.

title: Planning analysis for locally advanced XXXX : dosimetric and efficiency comparisons between intensity-modulated radiotherapy (IMRT), single-arc/partial-arc volumetric modulated arc therapy (SA/PA-VMAT).

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['mean lung dose', 'MLD']

answer: @entity2 :: (MESH:D008175,Disease) :: ['lung cancer']


abstract: BACKGROUND: The development of collaterals in @entity3181 has been described and these collaterals play an important role in the presentation of this disease. These collaterals are diagnostic and their use in management strategy has never been evaluated. This study aimed to investigate the indications, feasibility and necessity of invasive treatment for @entity1 with @entity3181 and to determine whether such a strategy is necessary for optimal management. METHODS: Twenty-nine @entity1 who had been treated at our unit were enrolled in this study. Based on physical and biochemical examination, and hemodynamic compensation by collaterals, 18 @entity1 underwent radiological intervention (group A), while the other 11 had no invasive treatment (group B). The related hemodynamic parameters were acquired when percutaneous angiography was performed. RESULTS: In group A, all @entity1 underwent successfully inferior vena cava (IVC) balloon angioplasty with or without stenting. Four @entity1 also underwent hepatic vein angioplasty. In these @entity1 , the mean IVC pressure before and after treatment was statistically different (29.3+/-9.2 vs 15.1+/-4.6 mmHg, P<0.01). The mean IVC pressure was much lower in group B than in group A (12.9+/-2.4 vs 29.3+/-9.2 mmHg, P<0.01), but there was no difference from that of the @entity1 after radiological treatment (12.9+/-2.4 vs 15.1+/-4.6 mmHg, P>0.05). Median follow-up was 32.3 months (mean 21.3 months; range 3-61 months). In the course of follow-up, the @entity1 in group A survived with good systemic status except for @entity850 in one @entity1 who underwent re-canalization of the IVC. In group B, 10 @entity1 had good systemic status except one @entity1 who had a meso-caval shunt because of deterioration. CONCLUSIONS: The rationale of "early diagnosis and early treatment" is not suitable for all @entity1 with @entity3181 . Satisfactory survival can be achieved in some @entity1 without invasive treatment, who are completely compensated by rich collaterals. Nonetheless, a positive treatment procedure should be performed if the @entity1 's situation worsens in the course of regular follow-up.

title: Necessity and indications of invasive treatment for XXXX .

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['re-stenosis']

entities_list: @entity3181 :: ('MESH:D006502', 'Disease') :: ['Budd-Chiari syndrome']

answer: @entity3181 :: (MESH:D006502,Disease) :: ['Budd-Chiari syndrome']


abstract: BACKGROUND: Recent clinical trials using @entity2467 + @entity1 cardiac stem cells (CSCs) demonstrated promising results in increasing cardiac function and improving quality of life. However, CSC efficiency is low, likely due to limited cell survival and engraftment after transplantation. The Rho-associated protein kinase (ROCK) inhibitor, @entity12223 , significantly increased cell survival rate, adhesion, and migration in numerous types of cells, including stem cells, suggesting a common feature of the ROCK-mediated apoptotic pathway that may also exist in @entity1 CSCs. In this study, we examine the hypothesis that pretreatment of @entity1 CSCs with @entity12223 protects cells from @entity632 ( @entity3105 ) induced apoptosis. METHODS AND RESULTS: @entity2467 + CSCs were cultured in CSC medium for 3-5 days followed by 48hr treatment with 0 to 10 M @entity12223 alone, 0 to 1.0 M @entity3105 alone, or @entity12223 followed by @entity3105 (48hrs). Cell viability, @entity137 , proliferation, morphology, migration, @entity522 activity, expression levels of apoptotic-related key proteins and @entity2467 + were examined. Results showed that 48hr treatment with @entity12223 alone did not result in great changes in @entity2467 + expression, proliferation, @entity522 activity, or apoptosis; however cell viability was significantly increased and cell migration was promoted. These effects likely involve the ROCK/Actin pathways. In contrast, 48hr treatment with @entity3105 alone dramatically increased @entity522 activity, resulting in cell death. Although @entity12223 alone did not affect the expression levels of apoptotic-related key factors (p- @entity584 , @entity584 , @entity588 , @entity1836 , @entity589 , cleaved @entity522 , and @entity522 ) under basal conditions, it significantly inhibited the @entity3105 -induced increase in cleaved @entity522 and reduced cell death under @entity3105 treatment. CONCLUSIONS: We conclude that preconditioning @entity1 CSCs with @entity12223 significantly reduces @entity3105 -induced cell death and possibly involves the cleaved @entity522 and ROCK/Actin pathways. The beneficial effects of @entity12223 may be applied to stem cell-based therapy to increase cell survival rates after transplantation or to act as a cardiac protective agent for @entity3105 -treated @entity5 @entity1 .

title: Rho-Associated Kinase Inhibitor ( @entity12223 ) Attenuates @entity632 -Induced Apoptosis of XXXX Cardiac Stem Cells.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['Doxorubicin']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

answer: @entity1 :: (9606,Species) :: ['Human']